Makary Out, Diamantas Acting Commissioner, Gene Therapy Stack Note

Marty Makary resigned 12:43 PM ET Tuesday May 12 after 13 months. Kyle Diamantas, former top FDA food chief, named acting commissioner. Kennedy made the call, White House signed off. Tenure marked by mass layoffs, senior leader churn, and policy fights with lawmakers, drugmakers, and Trump.

The trigger events that took him out tell you the trade. Pushback on biopharma over inconsistent medicine reviews. The Replimune RP1 melanoma CRL was the headline grievance, second rejection for the viral oncolytic. Plus the abortion pill telehealth fight, the flavored vape reversal, and broad pharma industry frustration with regulatory inconsistency.

Friday Tape Already Front Ran This

Friday May 8 the WSJ broke the plan to fire story. Tape repriced the rejection-victims basket immediately. REPL +21.86 percent, QURE +14.53 percent, BHVN +1.23 percent. Today is the confirmation leg.

The Trade Structure

Three concentric rings of beneficiary.

Ring 1, direct rejection victims, highest beta to the news.

REPL, Replimune, RP1 melanoma CRL was the grievance flashpoint. New leadership opens the door to a refiled BLA path or different review posture.

QURE, uniQure, AMT-130 Huntington single-arm regulatory template, the kind of accelerated pathway under question through Makary tenure.

CAPR, Capricor, deramiocel DMD cardiomyopathy CRL, another rejected name with refile optionality.

STLT, Stealth Biotherapeutics, elamipretide rejection. Same setup.

Ring 2, gene therapy and cell therapy sector broadly.

The Makary-Prasad axis was perceived as the bottleneck on accelerated approval pathways for one-time genetic medicines. Names that benefit from regulatory thaw include CRSP, NTLA, BEAM, SANA, CRBU, ARWR, IRD, MGTX, RGNX, IBRX, plus QURE again. ATRA also fits this ring with its allogeneic platform.

Ring 3, PROTAC, RNA editing, novel modality platforms.

ARVN as first commercial PROTAC, the Makary tenure approved vepdegestrant so the precedent matters. PRQR and ABCL fit the modality thaw thesis.

Conference Week Leverage Is The Setup

Five Ring 2 names present at BofA this week. Coverage just shifted, all become P1 must cover.

CRSP, Tuesday 3:40 PM CT fireside, gene editing leader, sickle cell franchise plus pipeline.

SANA, Tuesday 4:20 PM CT, Steve Harr CEO business overview, in vivo cell therapy story now riding the LEGN tailwind from this morning plus the regulatory tailwind.

NTLA, Tuesday 5:40 PM CT fireside, in vivo CRISPR platform leader.

CRBU, Wednesday 10:40 AM CT fireside Miami Tier 3.

IMTX, multi-day at BofA plus ASGCT Boston plus PEGS Boston same week, TCR platform with PRAME.

The Q&A on regulatory posture under new FDA leadership becomes the main attraction at every one of these slots. Management commentary on whether the regulatory environment is shifting is the catalyst that prints overnight.

This Morning's Earnings Wire Just Got Material Tailwind

IRD Miami Tier 1 ophthalmic gene therapy printed the LCA5 pediatric data and RDEP designation this morning. Five program pipeline with $90M cash and runway to 2029. New FDA leadership materially helps the timing and posture of the Phase 3 LCA5 dosing trigger plus BEST1 readout in September. This setup is now stacked.

LEGN print of $597M CARVYKTI plus the regulatory thaw is a double tailwind for the entire cell therapy vertical.

ARVN beating earnings while the PROTAC platform stays in the regulatory good graces just got harder to argue against. Pfizer-partnered first commercial PROTAC under the prior regime is now in a friendlier environment.

Who Diamantas Is

Kyle Diamantas was the FDA food chief. Acting role means he is a placeholder while Kennedy and the administration vet a permanent replacement. Names floated for permanent role include Stephen Hahn from the first Trump tenure, more pharma-aligned of the floated names, and Brett Giroir. Permanent nomination timing matters because acting commissioners typically do not drive major policy shifts, they hold the line until the permanent pick clears.

The implication for the trade is that the acute reaction is the leak-to-confirmation pop already largely priced into Ring 1 from Friday. The sustained move depends on the permanent nomination and the early posture signals from the new regime. Hahn would be the most bullish read for biopharma. A wildcard nominee from outside conventional FDA leadership channels would extend uncertainty.

Risk Frame

Diamantas in an acting role is not a structural change yet. Replimune second CRL still stands until the agency takes affirmative action on a refile. The trade is a regulatory regime expectation shift, not an approval pathway opening. The risk is that the next permanent commissioner takes a similar or stricter posture, especially on accelerated approval, in which case Ring 1 retraces Friday gains and Ring 2 gives back the conference week premium.

The Wednesday Senate Approps testimony Makary was scheduled for is now cancelled or reassigned. Whoever takes that slot will be the first public read on new agency posture, watch the language carefully.

Bottom Line For The Stack

Tape direction today, gene therapy and cell therapy positive. Conference week becomes Q&A driven on regulatory posture. The trade has two legs, the confirmation pop already happening this afternoon and the second leg on permanent nominee plus first major policy decision under Diamantas.

Coverage shifts this week mean every BofA gene therapy and cell therapy slot becomes a priority listen. Tuesday is the big day for the trade, three of the five Ring 2 conference names present today.

.